Abstract

BackgroundTuberculosis (TB) and HIV are among the risk factors for deep vein thrombosis (DVT). There are several challenges in the management of DVT patients with TB-HIV co-infection including drug-drug interactions and non-adherence due to pill burden.MethodsHIV infected patients starting treatment for TB were identified and followed up two weekly. Cases of DVT were diagnosed with Doppler ultrasound and patients were initiated on oral anticoagulation with warfarin and followed up with repeated INR measurements and warfarin dose adjustment.ResultsWe describe 7 cases of TB and HIV-infected patients in Uganda diagnosed with DVT and started on anticoagulation therapy. Their median age was 30 (IQR: 27–39) years and 86 % were male. All patients had co-medication with cotrimoxazole, tenofovir, lamivudine and efavirenz and some were on fluconazole. The therapeutic range of the International Normalization Ratio (INR) was difficult to attain and unpredictable with some patients being under-anticoagulated and others over-anticoagulated. The mean Time in Therapeutic Range (TTR) for patients who had all scheduled INR measurements in the first 12 weeks was 33.3 %. Only one patient among those with all the scheduled INR measurements had achieved a therapeutic INR by 2 weeks. Four out of seven (57 %) of the patients had at least one INR above the therapeutic range which required treatment interruption. None of the patients had major bleeding.ConclusionWe recommend more frequent monitoring and timely dose adjustment of the INR, as well as studies on alternative strategies for the treatment of DVT in TB-HIV co-infected patients.

Highlights

  • Tuberculosis (TB) and Human Immunodeficiency virus (HIV) are among the risk factors for deep vein thrombosis (DVT)

  • The risk of deep vein thrombosis (DVT) is one and a half times higher among patients with tuberculosis (TB) compared to those without TB [1] due to a hypercoagulable state which occurs among patients with TB resulting from endothelial dysfunction due to the mycobacteria, increased fibrinogen, fibrin, tissue plasminogen activator, decreased anti-thrombin III [2, 3] and use of rifampicin especially in the first two weeks following TB treatment

  • Several case series have discussed the occurrence of thrombosis in patients with TB [10, 11] and in those with HIV [12, 13], in this case series we demonstrate the challenges encountered when trying to achieve an International Normalized Ratio (INR) within the therapeutic window with warfarin in this population of TB-HIV co-infected patients

Read more

Summary

Introduction

Tuberculosis (TB) and HIV are among the risk factors for deep vein thrombosis (DVT). There are several challenges in the management of DVT patients with TB-HIV co-infection including drug-drug interactions and non-adherence due to pill burden. The risk of deep vein thrombosis (DVT) is one and a half times higher among patients with tuberculosis (TB) compared to those without TB [1] due to a hypercoagulable state which occurs among patients with TB resulting from endothelial dysfunction due to the mycobacteria, increased fibrinogen, fibrin, tissue plasminogen activator, decreased anti-thrombin III [2, 3] and use of rifampicin especially in the first two weeks following TB treatment. Several challenges due to drug-drug interactions occur during the management of DVT in patients co-infected with HIV and TB. Several case series have discussed the occurrence of thrombosis in patients with TB [10, 11] and in those with HIV [12, 13], in this case series we demonstrate the challenges encountered when trying to achieve an International Normalized Ratio (INR) within the therapeutic window with warfarin in this population of TB-HIV co-infected patients

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call